COVID19 inhibitors: A prospective therapeutics

Area of Science:

• * Pharmaceutical Sciences
• * Virology
• * Medicinal Chemistry

Background:

• * Coronavirus disease (COVID-19) necessitates novel therapeutic strategies.
• * Rational drug design and identification of potent drug molecules are crucial for developing effective treatments.
• * Existing drug classes, including nucleotide analogs and anti-inflammatory agents, show promise.

Purpose of the Study:

• * To review drug design strategies against SARS-CoV-2.
• * To highlight potential COVID-19 therapies, including those with ethanolamine/propylamine fragments and heterocycles.
• * To discuss drugs in clinical trials for COVID-19, detailing their mechanisms of action.

Main Methods:

• * Comprehensive literature review of drug design principles and antiviral agents.
• * Analysis of drug candidates targeting viral proteins and host inflammatory responses.
• * Examination of clinical trial data for ongoing COVID-19 therapeutics.

Main Results:

• * Drug design strategies focus on improving binding affinity, potency, and selectivity.
• * Ethanolamine/propylamine fragments and heterocycles show potential antiviral activity.
• * Interleukin-6 inhibitors and nucleotide analogs are explored for COVID-19 treatment.

Conclusions:

• * Rational drug design offers promising avenues for COVID-19 therapies.
• * Combination approaches may enhance efficacy and mitigate side effects.
• * Ongoing clinical trials are vital for validating new SARS-CoV-2 treatments.